FDA Approves Otsuka's Jynarque as First Treatment to Kidney Decline in Rapidy Progressing Autosomal Dominant Polycystic Kidney Disease (ADPKD)

FDA Approves Otsuka's Jynarque as First Treatment to Kidney Decline in Rapidy Progressing Autosomal Dominant Polycystic Kidney Disease (ADPKD)

Submitted by admin on April 25, 2018 - 9:37am
Source: 
CP Wire
News Tags: 
Otsuka
Jynarque
autosomal dominant polycystic kidney disease
Headline: 
FDA Approves Otsuka's Jynarque as First Treatment to Kidney Decline in Rapidy Progressing Autosomal Dominant Polycystic Kidney Disease (ADPKD)
snippet: 
  • ADPKD, the fourth leading cause of end-stage renal disease,1,2 is a progressively debilitating genetic disease characterized by the development of fluid-filled cysts in the kidneys
  • Data from two phase 3 clinical trials showed that Jynarque (tolvaptan) slowed kidney function decline in adults at risk of rapidly progressing ADPKD

Do Not Allow Advertisers to Use My Personal information